Literature DB >> 15075909

Role of surgery in patients with stage IV melanoma.

Sandra L Wong1, Daniel G Coit.   

Abstract

PURPOSE OF REVIEW: The purpose of this brief review is to highlight recent advances in the surgical treatment of metastatic melanoma; to review factors important in the decision-making process of selecting the most appropriate patients for resection; and to discuss the current literature in the context of site of recurrence. RECENT
FINDINGS: While there are relatively few new findings on the surgical treatment of metastatic melanoma, recent reports do support prior observations in the field. The recently revised staging system for melanoma groups metastatic disease according to prognostic features. There is currently a great deal of interest in the use of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) to more accurately evaluate metastatic disease. The use stereotactic radiosurgery for brain metastases has expanded recently and adds to local treatment options. When procedures are performed with palliative intent, treatment goals must be clearly defined and communicated among the patient, family and surgeon. Improved understanding of the goals of palliative surgery may be facilitated by the concept of a palliative triangle, which helps define the decision making process among the patient, family members, and surgeon.
SUMMARY: Metastatic melanoma is usually associated with a dismal prognosis. When a procedure is performed with palliative intent, appropriately selected patients usually experience reliable relief of symptoms and improved quality of life. Improved survival after a complete resection with curative intent is often predicted by good performance status, longer disease-free interval, limited extent of metastatic disease, and less aggressive tumor biology.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15075909     DOI: 10.1097/00001622-200403000-00013

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  15 in total

1.  Selected patients with metastatic melanoma may benefit from liver resection.

Authors:  Paulo Herman; Marcel Autran C Machado; André Luis Montagnini; Luiz A C D'Albuquerque; William A Saad; Marcel C C Machado
Journal:  World J Surg       Date:  2007-01       Impact factor: 3.352

2.  Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib.

Authors:  Niloofar Fadaki; Servando Cardona-Huerta; Lea Martineau; Suresh Thummala; Shih-Tsung Cheng; Steve R Bunker; Richard Garcia-Kennedy; Wei Wang; David Minor; Mohammed Kashani-Sabet; Stanley P L Leong
Journal:  BMJ Case Rep       Date:  2012-10-22

3.  Differential expression patterns of capping protein, protein phosphatase 1, and casein kinase 1 may serve as diagnostic markers for malignant melanoma.

Authors:  Daxin Sun; Mian Zhou; Claudia M Kowolik; Vijay Trisal; Qin Huang; Kemp H Kernstine; Fangru Lian; Binghui Shen
Journal:  Melanoma Res       Date:  2011-08       Impact factor: 3.599

4.  Whole-body diffusion-weighted imaging: is it all we need for detecting metastases in melanoma patients?

Authors:  Giuseppe Petralia; Anwar Padhani; Paul Summers; Sarah Alessi; Sara Raimondi; Alessandro Testori; Massimo Bellomi
Journal:  Eur Radiol       Date:  2013-07-25       Impact factor: 5.315

5.  Surgical resection for bulky or recurrent axillary metastatic melanoma.

Authors:  Amber L Shada; Dustin M Walters; Shannon N Tierney; Craig L Slingluff
Journal:  J Surg Oncol       Date:  2011-08-08       Impact factor: 3.454

6.  A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430.

Authors:  Jeffrey A Sosman; James Moon; Ralph J Tuthill; James A Warneke; John T Vetto; Bruce G Redman; P Y Liu; Joseph M Unger; Lawrence E Flaherty; Vernon K Sondak
Journal:  Cancer       Date:  2011-03-31       Impact factor: 6.860

Review 7.  [Therapy of malignant melanoma. First-, second- and pathogenesis-oriented third-line therapies].

Authors:  K Rass; D Tadler; W Tilgen
Journal:  Hautarzt       Date:  2006-09       Impact factor: 0.751

8.  Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy.

Authors:  Janne Horn; Jørgen Lock-Andersen; Helle Sjøstrand; Annika Loft
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04-04       Impact factor: 9.236

9.  Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy.

Authors:  R Taylor Ripley; Jeremy L Davis; Jacob A Klapper; Aarti Mathur; Udai Kammula; Richard E Royal; James C Yang; Richard M Sherry; Marybeth S Hughes; Steven K Libutti; Donald E White; Seth M Steinberg; Mark E Dudley; Steven A Rosenberg; Itzhak Avital
Journal:  Ann Surg Oncol       Date:  2009-09-24       Impact factor: 5.344

Review 10.  Optimal management of metastatic melanoma: current strategies and future directions.

Authors:  Marta Batus; Salman Waheed; Carl Ruby; Lindsay Petersen; Steven D Bines; Howard L Kaufman
Journal:  Am J Clin Dermatol       Date:  2013-06       Impact factor: 7.403

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.